[{"address1": "520 Newport Center Drive", "address2": "Suite 1200", "city": "Newport Beach", "state": "CA", "zip": "92660", "country": "United States", "phone": "949 284 4555", "website": "https://www.evolus.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.", "fullTimeEmployees": 322, "companyOfficers": [{"maxAge": 1, "name": "Mr. David  Moatazedi", "age": 46, "title": "President, CEO & Director", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 1747170, "exercisedValue": 0, "unexercisedValue": 4271378}, {"maxAge": 1, "name": "Ms. Sandra  Beaver", "age": 46, "title": "Chief Financial Officer", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 740146, "exercisedValue": 0, "unexercisedValue": 62165}, {"maxAge": 1, "name": "Dr. Rui  Avelar C.CFP, Dip.SportMed, M.D.", "age": 62, "title": "Chief Medical Officer and Head of Research & Development", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 823187, "exercisedValue": 0, "unexercisedValue": 214209}, {"maxAge": 1, "name": "Mr. Nareg  Sagherian", "title": "Head of Global Investor Relations & Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jeffrey J. Plumer", "title": "General Counsel", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kurt  Knab", "title": "Vice President of Sales", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tomoko  Yamagishi-Dressler", "title": "Chief Marketing Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jessica  Novak", "title": "Senior Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 6, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1735689600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 10.51, "open": 12.77, "dayLow": 12.74, "dayHigh": 14.49, "regularMarketPreviousClose": 10.51, "regularMarketOpen": 12.77, "regularMarketDayLow": 12.74, "regularMarketDayHigh": 14.49, "beta": 1.315, "forwardPE": -187.22223, "volume": 2931400, "regularMarketVolume": 2931400, "averageVolume": 624259, "averageVolume10days": 786490, "averageDailyVolume10Day": 786490, "bid": 10.34, "ask": 15.0, "bidSize": 200, "askSize": 1100, "marketCap": 853573760, "fiftyTwoWeekLow": 9.25, "fiftyTwoWeekHigh": 17.82, "priceToSalesTrailing12Months": 3.4373112, "fiftyDayAverage": 12.005, "twoHundredDayAverage": 13.284875, "currency": "USD", "enterpriseValue": 898413696, "profitMargins": -0.22333999, "floatShares": 49801721, "sharesOutstanding": 63321500, "sharesShort": 5400784, "sharesShortPriorMonth": 5210222, "sharesShortPreviousMonthDate": 1732838400, "dateShortInterest": 1735603200, "sharesPercentSharesOut": 0.0853, "heldPercentInsiders": 0.123050004, "heldPercentInstitutions": 0.79427004, "shortRatio": 10.75, "shortPercentOfFloat": 0.0871, "impliedSharesOutstanding": 63321500, "bookValue": 0.093, "priceToBook": 144.94623, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -55460000, "trailingEps": -0.91, "forwardEps": 0.2, "enterpriseToRevenue": 3.618, "enterpriseToEbitda": -34.197, "52WeekChange": -0.09630269, "SandP52WeekChange": 0.23171377, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "EOLS", "underlyingSymbol": "EOLS", "shortName": "Evolus, Inc. Common Stock", "longName": "Evolus, Inc.", "firstTradeDateEpochUtc": 1518100200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "90cb1fd6-b636-380b-949e-bd8942fd419e", "messageBoardId": "finmb_229087176", "gmtOffSetMilliseconds": -18000000, "currentPrice": 13.48, "targetHighPrice": 27.0, "targetLowPrice": 20.0, "targetMeanPrice": 23.42857, "targetMedianPrice": 25.0, "recommendationMean": 1.57143, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 85035000, "totalCashPerShare": 1.343, "ebitda": -26272000, "totalDebt": 129875000, "quickRatio": 2.132, "currentRatio": 2.472, "totalRevenue": 248326000, "debtToEquity": 2205.008, "revenuePerShare": 4.106, "returnOnAssets": -0.09925, "grossProfits": 173688992, "freeCashflow": -7398125, "operatingCashflow": -21994000, "revenueGrowth": 0.221, "grossMargins": 0.69944, "ebitdaMargins": -0.1058, "operatingMargins": -0.21355, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-22"}]